Cellectar CEO granted 250,000 stock options

Cellectar Biosciences President & CEO James V. Caruso received a grant of stock options to acquire 250,000 shares of common stock at an exercise price of $3.14 per share.

Rhea-AI Filing Summary

Cellectar Biosciences President & CEO James V. Caruso received a grant of stock options to acquire 250,000 shares of common stock at an exercise price of $3.14 per share. These options were contingently granted on May 28, 2026, subject to stockholder approval of the amended 2021 Stock Incentive Plan.

Stockholders approved the amended plan at Cellectar’s 2026 Annual Meeting of Stockholders on July 7, 2026, activating the grant. The options expire on May 28, 2036 and vest over three years, with one-third vesting on May 28, 2027 and the remainder vesting in 24 equal monthly installments thereafter.

Insider Trade Summary

Grant/Award: 250,000 shares

Grant/Award 1 txn

Insider CARUSO JAMES V

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	250,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 250,000 contracts (Direct)

Footnotes (2)

1. F1. This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.
2. F2. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026

Key Figures

Option grant size: 250,000 options Exercise price: $3.14 per share Total derivatives after grant: 250,000 options +3 more

6 metrics

Option grant size 250,000 options Stock option grant to CEO for common stock

Exercise price $3.14 per share Exercise price of CEO stock options

Total derivatives after grant 250,000 options Total options held following this transaction

Option expiration date May 28, 2036 Expiration of the CEO stock options

Vesting start May 28, 2027 One-third of options vest on first anniversary

Remaining vesting period 24 monthly installments Two-thirds vest over 24 months after first anniversary

Key Terms

Stock option (right to buy), exercise price, vesting, 2021 Stock Incentive Plan, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 3.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This option shall vest over a period of three years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

2021 Stock Incentive Plan financial

"approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan"

Annual Meeting of Stockholders financial

"at Cellectar's 2026 Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cellectar Biosciences (CLRB) report in this Form 4?

Cellectar Biosciences reported a compensation-related stock option grant to President & CEO James V. Caruso for 250,000 shares of common stock at a $3.14 exercise price. This is an options award, not an open-market stock purchase or sale.

How many Cellectar (CLRB) stock options were granted to the CEO and at what exercise price?

The CEO received stock options covering 250,000 shares of Cellectar common stock with an exercise price of $3.14 per share. The award represents a right to buy shares in the future rather than an immediate purchase of common stock in the market.

What is the vesting schedule for the new Cellectar (CLRB) CEO stock options?

The options vest over three years from May 28, 2026. One-third vests on the first anniversary, May 28, 2027, and the remaining two-thirds vest in 24 equal monthly installments beginning on that first anniversary, creating a gradual vesting profile tied to continued service.

When do the Cellectar (CLRB) CEO stock options expire and what is the term?

The stock options expire on May 28, 2036, giving a ten-year term from the contingent grant date of May 28, 2026. This long-dated expiration allows extended time for potential exercise, consistent with typical senior executive equity incentive structures.

Were the new Cellectar (CLRB) CEO stock options subject to shareholder approval?

Yes. The options were contingently granted on May 28, 2026, subject to stockholder approval of Cellectar’s amended 2021 Stock Incentive Plan. Stockholders approved the amended plan at the 2026 Annual Meeting on July 7, 2026, which finalized and activated the award.

Does this Cellectar (CLRB) Form 4 indicate any open-market buying or selling by the CEO?

No. The Form 4 reflects a grant of stock options coded as a grant, award, or other acquisition, not an open-market purchase or sale of common stock. It represents equity-based compensation, giving the CEO a future right to buy shares at $3.14 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 09:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARUSO JAMES V

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$3.14	07/07/2026(1)		A		250,000		(2)	05/28/2036	Common stock	250,000	$0	250,000	D

Explanation of Responses:

1. This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.

2. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026

	/s/ Chad Kolean, attorney-in-fact for James V. Caruso	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)